Seaport Global Securities reissued their buy rating on shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) in a report published on Friday, Marketbeat Ratings reports. The firm currently has a $5.00 price target on the biotechnology company’s stock. Seaport Global Securities also issued estimates for Pluristem Therapeutics’ Q3 2018 earnings at ($0.09) EPS.

PSTI has been the subject of a number of other reports. Maxim Group upgraded Pluristem Therapeutics from a hold rating to a buy rating and set a $2.00 price target for the company in a research report on Monday, June 19th. HC Wainwright set a $4.00 price target on Pluristem Therapeutics and gave the stock a buy rating in a research report on Thursday, August 17th. ValuEngine upgraded Pluristem Therapeutics from a strong sell rating to a sell rating in a research report on Monday, October 2nd. Finally, Zacks Investment Research downgraded Pluristem Therapeutics from a hold rating to a sell rating in a research report on Friday, September 22nd. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company. The company currently has a consensus rating of Hold and an average price target of $4.13.

Shares of Pluristem Therapeutics (PSTI) opened at 1.56 on Friday. Pluristem Therapeutics has a 12-month low of $1.04 and a 12-month high of $1.65. The company’s 50-day moving average is $1.35 and its 200-day moving average is $1.32. The company’s market capitalization is $152.06 million.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at

A hedge fund recently raised its stake in Pluristem Therapeutics stock. Renaissance Technologies LLC lifted its holdings in shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) by 9.1% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 1,553,800 shares of the biotechnology company’s stock after acquiring an additional 129,000 shares during the period. Renaissance Technologies LLC owned approximately 1.62% of Pluristem Therapeutics worth $1,911,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 4.47% of the company’s stock.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.

Receive News & Stock Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related stocks with our FREE daily email newsletter.